Clofazimine (CAS 2030-63-9)
See product citations (6)
QUICK LINKS
Clofazimine exhibits its antibacterial properties by effectively binding to DNA-dependent RNA polymerase, which impedes both transcription and replication processes. To assume its active form, this compound undergoes several metabolic transformations. These include hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. Notably, Clofazimine demonstrates a remarkable affinity for specific markers expressed at high levels in Mycobacterium tuberculosis strains, such as the ESX-1 secretion system protein. By specifically targeting these markers, it effectively inhibits the growth of the bacterial cells in culture. This dual mechanism of action, both at the molecular level through DNA-dependent RNA polymerase binding and at the cellular level through marker-specific inhibition, contributes to the potent antibacterial effects of Clofazimine.
Clofazimine (CAS 2030-63-9) References
- The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation. | Murashov, MD., et al. 2018. J Invest Dermatol. 138: 697-703. PMID: 29042210
- Clofazimine in Mycobacterium abscessus peritonitis: A pediatric case report. | Pinapala, A., et al. 2021. Perit Dial Int. 41: 104-109. PMID: 32148178
- Clofazimine Reduces the Survival of Salmonella enterica in Macrophages and Mice. | Nagy, TA., et al. 2020. ACS Infect Dis. 6: 1238-1249. PMID: 32272013
- Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. | Kadura, S., et al. 2020. J Antimicrob Chemother. 75: 2031-2043. PMID: 32361756
- Intrahistiocytic Storage of Clofazimine Crystals in a Cat. | Helgert, ND., et al. 2021. Vet Pathol. 58: 396-400. PMID: 33327886
- Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment. | de Castro, RR., et al. 2021. Int J Pharm. 602: 120655. PMID: 33915184
- Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts. | Tuvshintulga, B., et al. 2022. J Infect Dis. 225: 238-242. PMID: 34664651
- Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. | Kim, S., et al. 2022. Int J Antimicrob Agents. 59: 106509. PMID: 34958863
- Characterization of Clofazimine as a Potential Substrate of Drug Transporter. | Jony, MR., et al. 2022. Antimicrob Agents Chemother. 66: e0215821. PMID: 35254089
- In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus. | Schulthess, B., et al. 2022. Antimicrob Agents Chemother. 66: e0234621. PMID: 35420492
- Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of action. | Parvathaneni, V., et al. 2022. Life Sci. 306: 120843. PMID: 35908620
- Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection. | Brunaugh, AD., et al. 2022. Antimicrob Agents Chemother. 66: e0018622. PMID: 35943265
- Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro. | Howlader, S., et al. 2022. Antimicrob Agents Chemother. 66: e0056522. PMID: 36190267
- Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice. | Sriram, D., et al. 2022. Tuberculosis (Edinb). 137: 102268. PMID: 36228452
- Extemporaneously compounded liquid formulations of clofazimine. | Taneja, R., et al. 2023. Int J Tuberc Lung Dis. 27: 106-112. PMID: 36853102
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Clofazimine, 5 g | sc-234402 | 5 g | $198.00 |